Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01946204 · ClinicalTrials.gov registry record · Phase 3
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
A Phase 3 study of Prostatic Neoplasms, sponsored by Aragon Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 1,207
- Enrollment target
- 20
- Study locations
NCT01946204 is a Phase 3 study of Prostatic Neoplasms that is active but no longer recruiting, run by Aragon Pharmaceuticals. The registered enrollment target is 1,207 participants, above the 496-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (143% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT01946204, a Phase 3 study of Prostatic Neoplasms, is active but no longer recruiting, sponsored by Aragon Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,207 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate cancer.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Apalutamide
Study Locations (20)
California
- - Duarte
- - Fullerton
- - Laguna Woods
- - Los Angeles
- - Orange
- - Roseville
- - Sacramento
- - San Bernardino
- - San Diego
- - San Francisco
- - Santa Monica
- - Sherman Oaks
- - Stanford
- - Tarzana
- - Torrance
Arizona
- - Chandler
- - Tucson
Alabama
- - Birmingham
Alaska
- - Anchorage
Colorado
- - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,207 participants |
| Start Date | 2013-10-14 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01946204
The ClinicalTrials.gov registry entry for NCT01946204 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,207 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 496-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (143% higher). The listed sponsor is Aragon Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostatic Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01946204 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT01946204 about?
NCT01946204 is a clinical study titled "A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer". The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate cancer.
What is the current status of trial NCT01946204?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,207 participants. The study started on 2013-10-14. Estimated completion is 2027-12-31.
What conditions does trial NCT01946204 study?
This clinical trial studies the following conditions: Prostatic Neoplasms.
What interventions are being tested in trial NCT01946204?
The interventions under investigation include: Placebo (DRUG), Apalutamide (DRUG).
Who is sponsoring clinical trial NCT01946204?
This trial is sponsored by Aragon Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01946204 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
RECRUITING · Phase 3
-
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
RECRUITING · Phase 3
-
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
RECRUITING · Phase 3
-
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
ACTIVE NOT RECRUITING · Phase 3
-
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.